Eldridge Industries to Launch Eldridge, an Asset Management and Insurance Holding Company with $74 billion in AUM
Today, Eldridge Industries announced plans to launch Eldridge, an asset management and insurance holding company with approximately $74 billion in assets under management. Eldridge will be wholly owned by Eldridge Industries and consist of two divisions: Eldridge Capital Management and Eldridge Wealth Solutions.
Eldridge Capital Management will focus on four investment strategies – corporate credit, GP solutions, real estate credit, and sports, media, and entertainment – and will conduct business under the Eldridge brand. Eldridge Wealth Solutions, an insurance and retirement solutions platform, will be comprised of Eldridge’s wholly owned insurance companies, Security Benefit and Everly Life.
Eldridge will be managed by a newly formed Executive Committee, chaired by Todd Boehly, Chairman and CEO and controlling shareholder of Eldridge Industries. Mr. Boehly, in his capacity as Chairman of Eldridge’s Executive Committee, will be involved with strategic oversight and partnerships of both Eldridge Capital Management and Eldridge Wealth Solutions.
“Eldridge will bring together decades of collective experience, world-class structuring, proprietary origination expertise, and differentiated approaches to capitalize on what we believe to be the most attractive opportunity set in quite some time, and we are excited to enter this next chapter of growth,” said Mr. Boehly. “We are confident that the firm will provide the highest level of service and generate new, compelling investment opportunities.”
Tony Minella, Eldridge Industries Co-founder and President, who has worked alongside Mr. Boehly for approximately twenty-five years, will lead Eldridge Capital Management as Chief Executive Officer. Todd Gilbert and Nicholas Sandler will serve as Co-Presidents of Eldridge Capital Management.
Eldridge Wealth Solutions will be led by Doug Wolff as Chief Executive Officer and Joseph Wittrock as Chief Investment Officer.
Existing Eldridge Industries businesses and teams, including Maranon Capital, Security Benefit’s Corporate Credit team, Stonebriar Commercial Finance’s Investment team, Cain International’s Real Estate Credit team, and Panagram Structured Asset Management, will integrate under Eldridge Capital Management and be rebranded as follows:
- Eldridge Corporate Credit will be co-led by Jeffrey Forlizzi and Nicholas Sandler and invest across a broad spectrum of private, asset-backed, opportunistic, and structured credit. The strategy will thoroughly underwrite downside scenarios to provide a margin of safety and utilize a rigorous, fundamental-driven, and value-oriented approach emphasizing deep investment research while balancing company, industry, and macro risks.
- Eldridge GP Solutions will be led by David Lee and invest in market-leading businesses through attractive middle-market GP-led transactions, including GP-led single-asset continuation vehicles, direct GP-led transactions, and provide other comprehensive capital and liquidity solutions to GPs.
- Eldridge Real Estate Credit will be led by John Cole andtake a disciplined, patient approach to investment in real estate credit opportunities across the U.S., U.K., and Europe by investing in construction, bridge, and special situation opportunities across the capital structure, primarily in gateway cities with best-in-class sponsors and assets.
- Eldridge Sports, Media, and Entertainment will be led by Jeff Wilbur and make investments in private companies that create and own premium intellectual property that can be distributed and monetized in multiple ways within the sports, media, and entertainment sectors.
Eldridge will have offices in New York, Greenwich, Beverly Hills, Chicago, Dallas, Atlanta, Overland Park, Des Moines, Topeka, London, and Abu Dhabi.
The transaction is expected to close in January 2025.
About Eldridge Industries
Eldridge Industries invests in businesses across the Insurance, Asset Management, Technology, Mobility, Sports & Gaming, Media & Music, Real Estate, and Consumer landscapes. The firm seeks to build and grow businesses led by proven management teams that have demonstrated leadership and experience to scale an enterprise. Eldridge Industries has offices in Miami, Greenwich, Beverly Hills, New York, and London. To learn more about Eldridge Industries, please visit eldridge.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205643580/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom